GVS (GVS) investor relations material

Executive summary

• Q1 2026 revenue reached €105 million, up 3.9% at constant exchange rates, with adjusted EBITDA at €25.9 million (+0.3%) and a margin of 24.6% (up 57 bps year-over-year).

• Adjusted net income was €10.7 million (margin 10.2%), while reported net profit reached €11.4 million, mainly due to positive FX effects.

• Net financial position stood at €249–249.8 million, with a leverage ratio of 2.3x.

• Organic growth was 3.9%, driven by volume (+2.4%) and pricing (+1.4%), despite a negative FX impact of €6.4 million, mainly from USD depreciation.

• The Group continued to invest in production facilities and automation, focusing on efficiency and flexibility.

Financial highlights

• Adjusted EBITDA margin improved by 57–60 bps year-over-year, mainly due to pricing actions.

• Adjusted net income margin was 10.2%, with a slight decline due to higher D&A from new plants and production transfers.

• Net financial position deteriorated by €9.7–10 million in Q1 due to working capital, but improved by €26–36 million year-over-year when excluding extraordinary CapEx.

• Working capital expected to have zero net impact by year-end, following typical seasonal trends.

• Cash and cash equivalents increased to €101.6 million from €78.7 million at year-end 2025.

Outlook and guidance

• FY 2026 guidance confirmed: low single-digit consolidated revenue growth at constant FX, with progressive acceleration expected through the year.

• Adjusted EBITDA margin expected to expand by 20–50 bps versus previous year.

• Leverage ratio targeted at approximately 1.8x by year-end 2026, excluding the impact of the voluntary partial tender offer.

• No significant impact from raw material inflation expected in Q2; incremental pricing to customers will offset cost increases.

• Strategic focus includes MedTech sub-division creation, Transfusion Medicine sales growth, Life Sciences customer validations, and Safety product ramp-up.